Chronic heart failure in adults: diagnosis and management

with preserved ejection fraction. See also recommendation 1.5.5. [2025] 1.5.5 For SGLT2 inhibitors recommended as options in NICE technology appraisal guidance for treating heart failure with preserved ejection fraction, see the guidance on: • empagliflozin (TA929, 2023) • dapagliflozin (TA902, 2023). For a short explanation of why the committee made the 2025 recommendation and how it might affect practice, see the rationale and impact section on treatment combinations for heart failure with preserved ejection fraction. Full details of the evidence and the committee's discussion are in evidence review D: MRA for heart failure with preserved ejection fraction. 1.6 Treating heart failure in people with chronic kidney disease 1.6.1 If the person's eGFR is 45 ml per minute per 1.73 m2 or less, consider lower starting doses and smaller dose increments for the medicine combinations covered by recommendations 1.4.1, 1.4.3, 1.4.4, and 1.5.1 to 1.5.5. [2018, amended 2025] 1.6.2 If the person's eGFR is less than 30 ml per minute per 1.73 m2, the specialist heart failure multidisciplinary team (MDT) should consider liaising with a renal physician. [2018, amended 2025] 1.7 Starting and monitoring medication use Tailoring treatment 1.7.1 Use the person's medical history and findings from their clinical assessment, their
